Elotuzumab as a novel anti-myeloma immunotherapy

Elotuzumab as a novel anti-myeloma immunotherapy

Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymph...

Full description

Bibliographic Details
Main Authors:	Sabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Mary Steinbach, Janet Weidner, Tim Luetkens, Djordje Atanackovic
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-08-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	antibodies cs1 elotuzumab immunotherapy monoclonal multiple myeloma slam family of receptors
Online Access:	http://dx.doi.org/10.1080/21645515.2017.1327487

Similar Items

Novel anti-myeloma immunotherapies targeting the SLAM family of receptors
by: Sabarinath Venniyil Radhakrishnan, et al.
Published: (2017-05-01)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
by: Friend R, et al.
Published: (2017-03-01)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
by: Liping Liu, et al.
Published: (2016-07-01)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
by: Chen WC, et al.
Published: (2017-07-01)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
by: Kerry S. Campbell, et al.
Published: (2018-11-01)

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
by: Fortunato Morabito, et al.
Published: (2022-07-01)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
by: Joseph Kauer, et al.
Published: (2023-11-01)

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms
by: Tatiana Pazina, et al.
Published: (2017-09-01)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
by: Emily Chu, et al.
Published: (2023-08-01)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020-11-01)

SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy
by: Pooya Farhangnia, et al.
Published: (2023-05-01)

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01)

Role and Mechanism of SLAMF7-SLAMF7 Signaling Pathway in Tumor Progression
by: WANG Yuanyuan, et al.
Published: (2020-04-01)

Editorial: Immunotherapy in Multiple Myeloma
by: Nicola Giuliani, et al.
Published: (2019-08-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE
by: Morgane Humbel, et al.
Published: (2021-03-01)

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines
by: Lawrence G. Lum, et al.
Published: (2020-05-01)

Immunotherapy in multiple myeloma
by: Yamna Jadoon, et al.
Published: (2021-01-01)

Immunotherapy in Multiple Myeloma
by: Cinnie Yentia Soekojo, et al.
Published: (2020-03-01)

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient
by: Christos Sachpekidis, et al.
Published: (2017-12-01)

Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
by: Antonio G. Solimando, et al.
Published: (2023-07-01)

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
by: Fabiola De Luca, et al.
Published: (2023-02-01)

Emerging agents and regimens for multiple myeloma
by: Yang Yang, et al.
Published: (2020-11-01)

Novel Experimental Drugs for Treatment of Multiple Myeloma
by: Offidani M, et al.
Published: (2021-03-01)

Multiple Myeloma: An Update
by: Khalil Al-Farsi
Published: (2013-01-01)

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma
by: Meera Mohan, et al.
Published: (2021-09-01)

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
by: Mattia D’Agostino, et al.
Published: (2020-11-01)

A Stepwise Screening Protocol for Multiple Myeloma
by: Marta Morawska, et al.
Published: (2023-02-01)

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
by: Laurens E. Franssen, et al.
Published: (2020-04-01)

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
by: Noémie Leblay, et al.
Published: (2020-05-01)

Targeted Therapies for Multiple Myeloma
by: Christopher Chang-Yew Leow, et al.
Published: (2021-04-01)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
by: Nadeem O, et al.
Published: (2020-10-01)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
by: Simone A. Minnie, et al.
Published: (2021-03-01)

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
by: Cirino Botta, et al.
Published: (2021-06-01)

New developments in the treatment of multiple myeloma – clinical utility of daratumumab
by: McEllistrim C, et al.
Published: (2017-04-01)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
by: Emma Verheye, et al.
Published: (2022-01-01)

In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma
by: Wafaa S. Khalaf, et al.
Published: (2019-08-01)

Immunotherapy for the treatment of multiple myeloma
by: Leora S. Boussi, et al.
Published: (2022-10-01)

The Role of Immunotherapy in Multiple Myeloma
by: Mehmet Kocoglu, et al.
Published: (2016-01-01)

Scleredema associated with immunoglobulin A-κ smoldering myeloma: a case report and review of the literature
by: B. S. D. P. Keragala, et al.
Published: (2019-05-01)